IXICO PLC - neuroimaging and digital biomarker analytics firm - Says it has been notified by an unnamed client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data. Says client will end its trial while it undertakes additional preclinical studies. Contracted revenue for this trial represented GBP3.3 million of the order book as at September 30, of which the company had expected to deliver GBP800,000 in revenue from it in the financial year that ends on the same date.
Current stock price: 71.00 pence, down 16% on Wednesday
Year-to-date change: down 31%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.